From @Breakingviews: GSK’s discounted valuation after hiving off its Advil making unit could lead to risky M&amp;As as the company is set to lose exclusivity by 2027 on a molecule contained in four of its HIV drugs, @aimeedonnellan explains  https://t.co/YBlisUnklK